Efficacy and Tolerance Study of an Oligopeptide with Potential Anti-Aging Activity

Athanasia Varvaresou¹, Spyridon Papageorgiou¹, Evangelia Protopapa¹, Alexandra Katsarou²

¹Department of Aesthetics and Cosmetology, School of Health & Caring Professions, Technological Educational Institution, Athens, Greece; ²Department of Dermatology and Venereology, University of Athens, Athens, Greece, “Andreas Syggros” Venereal & Skin Diseases Hospital of Athens, Athens, Greece.
E-mail: avarvares@teiath.gr, varvaresou@pharm.uoa.gr

Received September 14th, 2011; revised November 1st, 2011; accepted November 14th, 2011.

ABSTRACT

Background: Oligopeptide-20 acts as positive regulator of cell proliferation and increases collagen and hyaluronic acid levels in keratinocyte and fibroblast cultures. Methods: After randomization half the face of twenty volunteers was treated twice daily for two months with the oligopeptide-20 cream (0.003% w/w, 300 ppm) and the other half with the vehicle. Skin bioengineering was used to estimate the effects on human skin. Results: The average number and width of wrinkles (Sew, 11.7%, p < 0.05) and cyclic average roughness (cR3, 12.2%, p < 0.005) were improved. Sesc parameter, indicative of stratum corneum dehydration was affected almost equally by the oligopeptide and the vehicle cream (p < 0.1). Volunteers noted statistically significant improvement regarding fine wrinkles and skin brightness on the peptide treated side, whereas the skin smoothness was improved on both sides. No significant changes in pigmentation measured by Mexameter were recorded. No significant changes in transepidermal water loss values were demonstrated, indicating oligopeptide-20 does not affect the skin barrier. No serious adverse or side effects were observed. Additionally, the oligopeptide cream was not irritant according to 48 h semi-occluded patch test. Conclusion: Oligopeptide-20 could be a useful and safe ingredient of anti-aging cosmetics.

Keywords: Oligopeptide-20, Anti-Aging Cosmetics, Efficacy and Tolerance, Profilometry, Self-Evaluation, TEWL and Skin Barrier

1. Introduction

Peptides as cosmeceutical ingredients, evolved from research into wound healing and studies on growth stimulation of human skin fibroblasts [1,2]. In recent years there has been increased interest in the use of that signal peptides in the management of aging [3-5]. Palmitoyl pentapeptide-4 (Pal KTTKS) is a procollagen pentapeptide fragment [6] which stimulates collagen I and III and fibronectin production by fibroblasts in vitro and has been shown to decrease skin roughness and wrinkles and fine lines [7] after 4 month application. Copper tripeptide-1 is thought to improve skin firmness and texture, fine lines and hyperpigmentation [8]. Oligopeptide-20 is another synthetic peptide consisted of the following 12 amino acids: Arg-Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro [9]. It acts as positive regulator of cell proliferation and increases collagen and hyaluronic acid levels in keratinocyte and fibroblast cultures. In vitro decreases apoptosis rates and increases cell attachment, which is a significant part of wound healing and skin regeneration [10]. To the best of our knowledge, there is no study in the bibliography regarding the clinical efficacy of cosmetic products containing oligopeptide-20.

As a part of our research program on anti-aging and cosmeceutical agents [11-15], we thought it would be of interest to examine by means of a randomized, vehicle controlled, double blind study the anti-aging properties of a cream containing 0.003% w/w (300 ppm) of the newly synthesized oligopeptide-20. We have used five different assessment methods to examine the effect of topical oligopeptide-20 treatment on the skin: Four non-invasive, bioengineering, objective techniques proposed by EEMCO Group (European Group in Efficacy Measurement of Cosmetics and Other Topical Products) and subjective self-evaluation. Skin surface morphology was examined by a direct non-invasive method with the instrument Skin VisioscanVC98 [16]. Skin microtopography was examined by optical profilometry (negative rep-
lica method), which is a useful non-invasive method in trials estimating the effectiveness of anti-wrinkle preparations [17-22]. Pigmentation was examined by the melanin index measurement (Mexameter) [23,24]. The effect of the peptide on skin barrier was also investigated. Transepidermal water loss (TEWL) measurement can screen ingredients that have effect on barrier function and offer the possibility to monitor in vivo on human skin the effect of topical treatment in an objective and non-invasive way [25,26]. Additionally, assessment of skin tolerance of the oligopeptide-20 cream was performed [27,28].

2. Materials and Methods

2.1. Treatment Creams

Creams contained identical vehicle. The active cream contained oligopeptide-20 0.003% w/w (300 ppm). Oligopeptide-20 was donated by Cellco Chemicals Ltd (Athens, Greece), distributor in Greece of Caregen Co., Ltd (South Korea).

Ingredients: Aqua, C12-20 Acid PEG Ester, Glyceril Stearate (and) PEG-100 Stearate, Cetyl Alcohol, Dimethicone, Octyl Palmitate, Xanthan Gum, Propylene Glycol, Propylparaben, Methylparaben, Imidazolidinyl Urea, BHT.

2.2. Equipment


2.2.1. Efficacy Study

2.2.1.1. Volunteers

Twenty females and two males (age 35 - 75, mean age 55 years) were included in this study. They were selected according to following inclusion criteria:

Discontinuation of treatments by products containing retinoids, α-hydroxyacids and other anti-aging treatments at least six months before the beginning of the study.

2.2.1.2. Signed Informed Consent

Avoidance of medication such as steroid hormone replacement, birth control pills and vitamin supplements during the study period. At the baseline visit, the participants were instructed not to apply or take orally any other anti-wrinkle products/food supplements and not to apply at each visit, any product on the previous 12 hours.

2.2.1.3. Study Procedure

The procedure was done according to good clinical practice (GCP) guidelines. Volunteers were visited at the baseline (D0) and D20, D40 and D60.

Skin surface evaluation, skin microtopography, melanin content, transepidermal water loss and were measured before (D0), during (D20, D40) and after the treatment (D60) and self-evaluation was performed by the test subject before (D0) and after 2-month treatment (D60). Side effects were also evaluated by the volunteers.

Two coded 50 g vessels, marked right and left, respectively for use twice daily on each half of the face were distributed at the first visit. At each control used vessels were collected in order to allow calculation of the amount of cream used. Tests were carried out in a half face, double manner. The participants rested for a 20-min aclimatizing period before the measurements at a room temperature ranging between 19°C - 21°C and RH between 40% and 60%. The subject was seated in a comfortable armchair with closed eyes in order to relax. In this position measurements were done on the periocular skin surface.

2.2.1.4. Skin Surface Evaluation

The surface of living skin was analyzed by the direct non-invasive method using the instrument Skin Visioscan VC98 [16]. In Skin Visioscan technique the image of the skin is taken by a built in CCD-camera. The Surface Evaluation Living Skin (SELS) parameters Sew (wrinkles parameter), calculated from the average number and width of horizontal and vertical wrinkles and Sesc (scaliness parameter), representative of the dryness of stratum corneum, were evaluated [16]. The ideal moisturizing or anti-aging treatment should decrease Sew and Sesc.

2.2.1.5. Skin Microtopography

Skin Visiometer SV600FW (optical profilometry) is used for non-direct measurement of skin topography [17-22]. To obtain negative imprints of the examined skin area, fast hardened blue silicon and adhesive disks were used. The adhesive disk was layered onto the volunteer’s skin to delimit the investigated area, avoiding skin stretching during the application and keeping track of the specimen orientation. A small amount of silicone was then spread into the internal circular area delimited by the adhesive disk and left in situ for 15 minutes until dry. The disc was next removed obtaining a careful duplicate of the skin surface on the silicone.

The silicon replica was put on a special frame and inserted in the special device where a light source sending out parallel light and a video sensor CCD on the other side. The replica reproduces the skin as a negative i.e. wrinkles are reproduced as mountains as the silicone is thicker in that place. Cyclic average roughness parameter
(cR₃) was examined. cR₃ is the average roughness calculated by circular arrangement of the lines in order to compensate the influence from the direction of the wrinkles [19]. The ideal moisturizing or anti-aging treatment should decrease cR₃.

2.2.1.6. Melanin Measurement
Mexameter MX18 was used to estimate the activity of the oligopeptide on skin pigmentation [23,24].

2.2.1.7. Self-Assessment
Subjects were asked to provide an assessment of improvement or not at the end of the treatment relative to baseline for fine lines, skin brightness and skin smoothness. These variables were scored on a scale of 1-4 indicating total (4), great (3), moderate (2), slight (1) and none (0).

2.2.1.8. Transepidermal Water Loss (TEWL)
TEWL measurements [25,26] were included to determine if the oligopeptide-20 affects skin barrier. Tewameter was used. In this instrument the water evaporation gradient, developed from the skin surface is measured by a probe that is placed perpendicularly on the skin site to be measured. The probe consists of an open cylinder containing two hygrosensors coupled with two thermistors placed at different distances from the skin surface. At both points, the relative humidity and temperature are measured and the corresponding vapour pressure is calculated. The difference between the vapour pressures at both points along the gradient is directly related to the rate of the evaporative water loss through the particular skin site.

2.2.1.9. Statistical Analysis
The improvement regarding Sew, Sesc and cR₃ were calculated according to the equation \[[\text{ScoreDn} - \text{ScoreD0}] / \text{ScoreD0}] \times 100\], where n: 20, 40 and 60.

The Wilcoxon signed rank tests were applied to study variations between measurements obtained the first and last day of the study and paired t tests between measurements of the active and vehicle side at D20, D40 and D60.

All the analyses were two-tailed. A p value < 0.05 was considered statistically significant, whereas p value < 0.1 was considered suggestive and p < 0.5 side preferred.

The data was analyzed using the Statmost statistical package.

2.2.2. Safety Evaluation
In order to evaluate the tolerability and the potential irritant power of the cream containing oligopeptide-20, 13 subjects both females and males, with an age between 18 - 70 years have been selected for the test, following the under mentioned inclusion criteria: 1) good state of general health; 2) no dermatopathies; 3) no pharmacological treatment in progress; 4) promise not to change usual daily routine; 5) no atopy. The test involves single application, 48 h semi-occluded patch test. The equipment used for the semi-occluded patch is composed of a small cavity of 0.64 cm² with a filter tissue at the bottom which is made to receive the product to test. All this is fixed to a hypoallergenic non woven adhesive tape. Treatment sites (back of the volunteers) are assessed before the first application of 0.02 ml test material (baseline) and after treatment at 30 minutes after patch removal. Negative controls (empty patch) are used to facilitate evaluation. The quantification of the skin irritation is given through a numeric scale. The average irritant score of the product is calculated from the average of the quotations obtained for each volunteer, allowing ranking from “non irritant to very irritant”. The reactions were evaluated according the following arbitrary scale [27,28].

Erythema
No erythema: 0, Light erythema (hardly visible): 1, Clearly visible erythema: 2, Moderate erythema: 3, Serious erythema (dark red with possible formation of light eschars): 4.

Edema
No edema: 0, Very light edema (hardly visible): 1, Light edema: 2, Moderate edema (about 1 mm raised skin): 3, Strong edema (extended swelling even beyond the application area): 4.

The index of average irritation was classified according amended Draize system: Non irritating: 0.5, 0.5 - 2.0: slightly irritating, 2.0 - 5.0: moderately irritating, 5.0 - 8.0 (highly irritating).

3. Results and Discussion
Of those recruited in the ant-aging evaluation, 20 of 22 subjects completed the 2 month treatment period. The results of 20 subjects were analyzed. None abandoned the study for adverse events or serious side effects. The most common side effect reported was dryness (Table 1). Dryness remained during the 2 month treatment and has to be mainly attributed to the poor synthesis of both creams in emollient ingredients, since the above symptoms were recorded at almost equal ratios for both the active and vehicle cream. No irritant or allergic reactions were documented during the test period.

We used direct non-invasive Visioscan VC98 technique [16] in order to evaluate skin surface. Regarding our study, Sew parameter indicative of number and width of horizontal and vertical wrinkles showed a decrease of 11.7% (p < 0.05) in the case of active side. The decrease for the vehicle side was remarkably lower (5.5%, p < 0.05) (Figure 1). Sesc parameter, indicative of dryness of stratum corneum seemed to be affected almost equally.
Table 1. Protocol of side effects (%) recorded on the active side and vehicle side by the subjects included in the trial. A test subject could report more than one side effect.

<table>
<thead>
<tr>
<th></th>
<th>D20 Active</th>
<th>D20 Vehicle</th>
<th>D40 Active</th>
<th>D40 Vehicle</th>
<th>D60 Active</th>
<th>D60 Vehicle</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. No side-effect</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B. Feeling of warmth in the skin</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C. Stinging</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>D. Redness</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>E. Desquamation</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>F. Dryness</td>
<td>50</td>
<td>50</td>
<td>20</td>
<td>50</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>G. Itching</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>H. Ocular intolerance</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

by the oligopeptide and the vehicle cream in a rather statistically suggestive manner (p < 0.1) (Figure 2).

We used optical profilometry (negative skin replicas) in order to evaluate skin microtopography, as well [17-22]. To date most of the non-invasive methods of quantification of cutaneous relief have consisted of the replicas. The relief profile is measured by optical technique. The metal industry has for several years defined and standardized the parameters used for characterization of the surface area of the metals. These parameters are the ones used for profilometric analysis of cutaneous microrelief.

The major parameters cited in the literature for skin surface are R1, R2 and R3 [19]. The measuring of these parameters is of importance for the discussion of the actual efficacy of the products on wrinkles and skin roughness, although clinical diversity and skin microrelief and wrinkles can hardly be reduced to the measurement of two or three parameters. As age increased, an increase of roughness parameters is observed [19].

In our study, a gradual improvement of cyclic roughness (cR3) was observed during treatment for both sides. The cR3 showed an overall decrease of 12.2% in the case of active side, whereas the decrease was almost the half (6.4%) for the vehicle side (Figure 3).

Regarding pigmentation, no identified influence on melanin content was recorded either in peptide- or vehicle-treated half face.

In the self-assessment 85% of the subjects (17 of 20, p < 0.005) claimed that the active side showed different degrees of improvement in fine wrinkles with a median of 1.35 (slight to moderate) while 65% (13 of 20, p < 0.005) claimed the vehicle treated side had improved with a median of 0.75 (rather slight). 80% of the subjects (16 of 20, p < 0.005) reported slight improvement of skin brightness in active side, while 55% (11 of 20, p < 0.005)
claimed none to slight improvement (median 0.55) in the vehicle side (Table 2). The results of self-assessment were in accordance with the data obtained by the bioengineering measurement. The recorded improvement of fine wrinkles by the 85% of the volunteers on the peptide-treated half correlates well with the decrease in wrinkles (Sew, D60, p < 0.05) and decrease in roughness (cR3, D60, p < 0.005). Only the slight improvement in skin brightness recorded by 80% of the volunteers on the active side is not confirmed by the Mexameter measurements, since the treatment did not reduce the extent and number of hyperpigmented spots on the face nor changed skin color as was measured by Mexameter. These subject-perceived benefits may be due to a “halo-effect” —subjects received a desired skin improvement on the peptide-treated side and translated that to a total improvement across benefit areas. Therefore, the combination of self-assessment with the bioengineering methods seems necessary.

Disturbances in biophysical properties of the skin during irritant reaction induced by exposure to cosmetic ingredients may be assessed by several non-invasive methods. The most popular one involves determinations of transepidermal water loss (TEWL), stratum corneum hydration, skin pH and evaluation of erythema and edema and skin blood flow [29]. No significant changes in transepidermal water loss values were demonstrated by either active or vehicle cream indicating oligopeptide-20 does not affect the skin barrier function. The possible irritating power of the tested peptide was evaluated according single application, 48 h semi-occluded patch test. Neither erythema or edema after the

Copyright © 2011 SciRes.
Table 2. Subjective evaluation at D60.

<table>
<thead>
<tr>
<th>Volunteer</th>
<th>Fine Lines</th>
<th></th>
<th>Skin Brightness</th>
<th></th>
<th>Skin Smoothness</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Active side</td>
<td>Vehicle side</td>
<td>Active side</td>
<td>Vehicle side</td>
<td>Active side</td>
<td>Vehicle side</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>13</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>14</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>16</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>17</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>19</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>20</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Total score</td>
<td>27</td>
<td>15</td>
<td>20</td>
<td>11</td>
<td>34</td>
<td>28</td>
</tr>
<tr>
<td>Median score*</td>
<td>1.35</td>
<td>0.75</td>
<td>1</td>
<td>0.55</td>
<td>1.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Percentage**</td>
<td>85</td>
<td>65</td>
<td>80</td>
<td>55</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

\( p^{***} \) <0.005 <0.005 <0.5

* total score ; ** Number of volunteers reported improvement \( \times 100 ; *** \) Paired two-tailed t test between active and vehicle side.

Further studies to elucidate possible mechanism of action and optimal dosage treatment periods are warranted. Although, the penetration and localization of the liposome form of oligopeptide-20 has been captured by fluorescence microscope, the labeled peptide being observed in epidermis and dermis [10], cutaneous penetration of pure oligopeptide will be in the future examined. At present we do not know which the ideal treatment period is. We think that a 4-month follow-up study would be useful in order to ensure the maximum improvement. The 0.003% w/w concentration of oligopeptide-20 in the cream used in the parent study is according to empirical data and is lower than maximum recommended (0.005% w/w, 500 ppm).

In conclusion, the application of the tested cream with 0.003% w/w oligopeptide-20 improves several clinical characteristics relating to skin aging, without damage to skin barrier or serious side effects. Furthermore, it is not irritating. The addition of moisturizing and emollient...
agents could enhance the anti-wrinkle activity of the oligopeptide and lead to the development of effective, innovative and safe formulations.

4. Acknowledgements

A part of the work was supported by Technological Educational Institution of Athens through “THALIS” action. We also would like to thank Caregen Co., (South Korea) manufacturer of oligopeptide-20 and the distributor in Greece, Cellco Chemicals Ltd. (Athens, Greece) for providing us with the oligopeptide-20.

REFERENCES


